Last reviewed · How we verify
MIYAIRI-BM
At a glance
| Generic name | MIYAIRI-BM |
|---|---|
| Also known as | Clostridium Butyricum MIYAIRI |
| Sponsor | Chang Gung Memorial Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- CBM588 Reduces Colorectal Polyp Recurrence (NA)
- The Clinical Application of Clostridium Butyricum Miyairisan for Motor and Non-motor Symptoms in Parkinson's Disease (NA)
- The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation (PHASE4)
- Probiotics for Gallstones in Post-bariatric Surgery Patients：A Prospective Randomized Trial (NA)
- Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MIYAIRI-BM CI brief — competitive landscape report
- MIYAIRI-BM updates RSS · CI watch RSS
- Chang Gung Memorial Hospital portfolio CI